Cargando…

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial

BACKGROUND/AIMS: To evaluate the cost-effectiveness of ranibizumab as either monotherapy or combined with laser therapy, compared with laser monotherapy, in the treatment of diabetic macular oedema (DME) causing visual impairment from a UK healthcare payer perspective. METHODS: A Markov model simula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitchell, Paul, Annemans, Lieven, Gallagher, Meghan, Hasan, Rafiq, Thomas, Simu, Gairy, Kerry, Knudsen, Martin, Onwordi, Henrietta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Group 2012
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329632/ https://www.ncbi.nlm.nih.gov/pubmed/22399690 http://dx.doi.org/10.1136/bjophthalmol-2011-300726

Ejemplares similares

Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment
por: Karst, Sonja G., et al.
Publicado: (2017)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
por: Wong, Yun, et al.
Publicado: (2016)

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
por: Thom, Howard HZ, et al.
Publicado: (2014)

Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema
por: Chakravarthy, Usha, et al.
Publicado: (2019)

Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review
por: Glanville, Julie, et al.
Publicado: (2014)

3-year-data of combined navigated laser photocoagulation (Navilas) and intravitreal ranibizumab compared to ranibizumab monotherapy in DME patients
por: Herold, Tina Rike, et al.
Publicado: (2018)

Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
por: Talks, S. James, et al.
Publicado: (2019)

Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment
por: Ziemssen, Focke, et al.
Publicado: (2017)

A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)
por: Stefanickova, Jana, et al.
Publicado: (2018)

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
por: Prünte, Christian, et al.
Publicado: (2016)

Clinically meaningful visual improvements and predictors of early vision gains with ranibizumab for diabetic macular oedema
por: Morse, Lawrence, et al.
Publicado: (2019)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review
por: Ford, John A, et al.
Publicado: (2012)

Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)
por: Sakamoto, Taiji, et al.
Publicado: (2021)

Two-year visual and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)
por: Sakamoto, Taiji, et al.
Publicado: (2022)

Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data
por: Ziemssen, Focke, et al.
Publicado: (2016)

Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study
por: Shimura, Masahiko, et al.
Publicado: (2020)

Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data
por: Sadda, Srinivas R., et al.
Publicado: (2019)

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab
por: Ebneter, Andreas, et al.
Publicado: (2016)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Analysis of DME/DME Navigation Performance and Ground Network Using Stretched-Front-Leg Pulse-Based DME
por: Kim, Euiho
Publicado: (2018)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema
por: Podkowinski, Dominika, et al.
Publicado: (2019)

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Rodríguez-Fernández, Carmen Antía, et al.
Publicado: (2022)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema
por: Mori, Yuki, et al.
Publicado: (2016)

Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies
por: Midena, Edoardo, et al.
Publicado: (2018)

Machine learning techniques for diabetic macular edema (DME) classification on SD-OCT images
por: Alsaih, Khaled, et al.
Publicado: (2017)

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)

The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema
por: Lang, Gabriele E., et al.
Publicado: (2017)

Costs of drugs for treatment of rheumatic diseases
por: Westhovens, Rene, et al.
Publicado: (2016)

Impact of metabolic control on macular thickness in diabetic macular oedema
por: Peng, Yi-Jie, et al.
Publicado: (2017)

Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies
por: Staurenghi, Giovanni, et al.
Publicado: (2018)

Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)
por: Korobelnik, Jean-Francois, et al.
Publicado: (2015)

GRAding of functional and anatomical response to DExamethasone implant in patients with Diabetic Macular Edema: GRADE-DME Study
por: Rodríguez-Valdés, Patricio J., et al.
Publicado: (2021)

Role of ranibizumab in management of macular degeneration
por: Singh, Rishi P, et al.
Publicado: (2007)

Comparative Evaluation Between Ranibizumab Combined with Laser and Bevacizumab Combined with Laser Versus Laser Alone for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Azad, Shorya Vardhan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cfbi6fu52q6q3g7rm4eumm097g